...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Revista da Associao Médica Brasileira >The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion
【24h】

The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion

机译：紫杉醇联合阿瓦斯汀治疗非小细胞肺癌恶性胸腔积液的临床疗效和安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary Objective: The current study aimed to investigate the clinical efficacy of paclitaxel combined with avastin for non-small cell lung cancer (NSCLC) patients diagnosed with malignant pleural effusion (MPE). Method: Total of 33 patients diagnosed with NSCLC as well as malignant pleural effusion were included. All of them received paclitaxel (175 mg/m2) and avastin (5 mg/kg). Clinical efficacy was evaluated using the total response rate, overall survival, progression-free survival and changes in MPE volume. Adverse events and rates of toxicities were examined as well. Results: The total response rate reached 77% while the overall survival and the median progression-free survival were respectively 22.2 months and 8.4 months. Toxicities of grade 3-4 consisted of neutropenia in 57% of patients, anemia in 17% of them, febrile neutropenia in 11%, as well as anorexia in 7%. No treatment-correlated deaths were found. Conclusion: Paclitaxel combined with avastin decreased MPE volume and increased survival rate of NSCLC patients via inhibiting vascular endothelial growth factor expression.
机译：摘要目的：本研究旨在探讨紫杉醇联合阿瓦斯汀在诊断为恶性胸腔积液（MPE）的非小细胞肺癌（NSCLC）患者中的临床疗效。方法：纳入33例确诊为NSCLC以及恶性胸腔积液的患者。他们都接受了紫杉醇（175 mg / m2）和avastin（5 mg / kg）。使用总缓解率，总生存期，无进展生存期和MPE量变化评估临床疗效。还检查了不良事件和毒性发生率。结果：总缓解率达到77％，总生存期和中位无进展生存期分别为22.2个月和8.4个月。 3-4级的毒性包括57％的患者中性粒细胞减少，其中17％的患者贫血，11％的发热性中性粒细胞减少以及7％的厌食症。没有发现与治疗相关的死亡。结论：紫杉醇联合阿瓦斯汀可通过抑制血管内皮生长因子的表达而降低MPE量并提高NSCLC患者的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号